|
|
|
|
|
|
|
Free Newsletters
Archive
My Subscriptions
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers
Regional News
US & Canada
Biotech Bay
Biotech Beach
Genetown
Pharm Country
BioCapital
BioMidwest
Bio NC
BioForest
Southern Pharm
BioCanada East
US Device
Europe
Asia
Market Summary
News
IPOs
Company Profiles
Companies
Events
Research Store
Biotech Events
Post an Event
Real Estate
Business Opportunities
|
|
|
|
|
News | News By Subject | News by Disease |
News By Date | Search News
|
|
|
Forest Laboratories, Inc. (FRX) Announces Preliminary Results of Annual Meeting of Shareholders
8/15/2012 10:08:52 AM
NEW YORK--(BUSINESS WIRE)--Forest Laboratories, Inc. (NYSE: FRX) (“Forest”) today announced that, based on the estimates of its proxy solicitor, preliminary results from its Annual Meeting indicate that shareholders have elected nine of the Company’s ten director nominees. The Forest nominees who were elected are: Nesli Basgoz, M.D.; Christopher J. Coughlin; Kenneth E. Goodman; Gerald M. Lieberman; Lawrence S. Olanoff, M.D., Ph.D.; Lester B. Salans, M.D.; Brenton L. Saunders; Howard Solomon; and Peter J. Zimetbaum, M.D. The preliminary results also indicate that one of Carl Icahn’s four nominees, Pierre Legault, has been elected to Forest’s Board. Mr. Icahn, a holder of approximately 10% of Forest’s outstanding shares, also nominated Eric Ende, designated leader of the Icahn Group’s proxy fight slate, Andrew Fromkin and Daniel Ninivaggi, none of whom were elected based on preliminary results.
|
|
|
|
|
|
|
|
|
|
|